Skip to main content
Clinical Trials/NCT03182985
NCT03182985CompletedNot Applicable

The Impact of Time Restricted Feeding (TRF) in Improving the Health of Patients With Metabolic Syndrome

University of California, San Diego1 site in 1 country35 target enrollmentStarted: July 28, 2017Last updated:
Conditions
Interventions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Enrollment
35
Locations
1
Primary Endpoint
Mean blood glucose

Study Overview

Brief Summary

The investigators intend to measure the health impact of a dietary intervention known as time restricted feeding (TRF) on patients with metabolic syndrome (three or more of: increased waist circumference, abnormal cholesterol levels, elevated blood pressure, or elevated blood sugar). The investigators will enroll patients with metabolic syndrome who eat for ≥ 14 hours per day and will ask participants to reduce daily oral intake to 10 hours per day. The investigators will assess the impact of this dietary change using measures obtained before and after a 12 week intervention period, including body mass index, blood pressure, various lab parameters and blood sugar levels (assessed using a continuous glucose monitor). The investigators will assess for compliance with TRF using a Smart Phone application (myCircadianClock (mCC) app).

Study Design

Study Type
Interventional
Allocation
Na
Intervention Model
Single Group
Primary Purpose
Prevention
Masking
None

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Waist circumference ≥ 102 cm (Men) or ≥ 88 cm (Women).
  • Triglycerides ≥ 150 mg/dL (or on drug treatment for elevated triglycerides).
  • Reduced HDL-C < 40 mg/dL (Men), < 50 mg/dL (Women) (or on drug treatment for reduced HDL-C).
  • Elevated blood pressure, systolic blood pressure ≥ 130 mmHg and/or diastolic blood pressure ≥ 85 mmHg (or treatment with antihypertensive drug with history of hypertension).
  • Elevated fasting glucose ≥ 100 mg/dL (or drug treatment of elevated blood glucose).
  • Age ≥18 years.
  • If patients are on cardiovascular medications (HMG coenzyme A reductase inhibitors (statins), other lipid modifying drugs (including over the counter drugs such as red yeast rice and fish oil), anti-hypertensive, anti-diabetes drugs), no dose adjustments will be allowed during the study period
  • Own a Smartphone with Apple iOperating System (OS) or Android OS. Baseline eating period is ≥ 14 hours per day.

Exclusion Criteria

  • Pregnant or breast-feeding.
  • Caregiver for a dependent requiring frequent nocturnal care/sleep interruptions. Shift workers with variable (e.g. nocturnal) hours.
  • Planned international travel during the study period.
  • Active tobacco abuse or history of treatment for alcohol abuse,
  • Known inflammatory and/or rheumatologic disease,
  • Known history of familial hypercholesterolemia,
  • History of major adverse cardiovascular event within the past 1 year (acute coronary syndrome (ACS), percutaneous coronary intervention, coronary artery bypass graft surgery, hospitalization for congestive heart failure, stroke/transient ischemic attack (TIA))
  • Uncontrolled arrhythmia (i.e. rate-controlled atrial fibrillation/atrial flutter are not exclusion criteria)
  • History of sudden cardiac death (SCD) or implantable cardiac defibrillator (ICD) implantation for any reason,
  • Known history of thyroid or adrenal disease,
  • Any history of malignancy,
  • Known history of type I diabetes,
  • Known history of major immune disease,
  • Eating disorder or bile syndrome,
  • History of cirrhosis
  • History of stage 4 or 5 chronic kidney disease or requiring dialysis
  • History of chronic obstructive pulmonary disease (COPD)
  • Known active infectious diseases,
  • Currently enrolled in a weight-loss or weight-management program,
  • On a special or prescribed diet for other reasons (e.g. Celiac disease),
  • Currently taking any medication that is meant for, or has known effect on, appetite,
  • Any history of surgical intervention for weight management,
  • History of venous thromboembolism.
  • Uncontrolled psychiatric disorder (including history of hospitalization for psychiatric illness)
  • History of known clotting or bleeding disorder(s)

Arms & Interventions

Time Restricted Feeding

Experimental

Patients will reduce daily oral intake to 10 hours per day

Intervention: Time Restricted Feeding (Behavioral)

Outcomes

Primary Outcomes

Mean blood glucose

Time Frame: 12 weeks

Measured using a continuous glucose monitoring (CGM) device

Secondary Outcomes

  • Insulin, triglycerides, hs-CRP levels(12 weeks)

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Pam Taub, MD

Associate Professor of Medicine

University of California, San Diego

Study Sites (1)

Loading locations...

Similar Trials